Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

Analyst Ratings

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (?)
Ratings Breakdown: 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $41.20 (70.25% upside)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetActions
5/31/2016Credit Suisse Group AGDowngradeOutperform -> Neutral$33.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016Citigroup Inc.Boost Price TargetBuy$29.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Morgan StanleyLower Price Target$71.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Goldman Sachs Group Inc.DowngradeBuy -> Neutral$65.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016Cowen and CompanyReiterated RatingBuy$65.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Portola Pharmaceuticals (NASDAQ:PTLA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.90)($0.82)$2.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.79)($0.76)$2.44 million$2.42 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/15/2013($0.72)($1.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.13)($1.13)($1.13)
Q2 20171($0.93)($0.93)($0.93)
Q3 20171($0.82)($0.82)($0.82)
Q4 20171($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Portola Pharmaceuticals (NASDAQ:PTLA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/2/2016William LisCEOSell5,675$23.86$135,405.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Portola Pharmaceuticals (NASDAQ:PTLA)
DateHeadline
07/21/16 08:51 AMPortola Pharmaceuticals Inc. (PTLA) Jumps 5.17% on July 20 - Equities.com
07/20/16 06:50 PMPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Expected To Post Sales Of $343.55 - Investor Newswire
07/20/16 06:50 PMPortola Pharmaceuticals, Inc. (NASDAQ:PTLA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 06:50 PMIs Buying Portola Pharmaceuticals Inc Here a Winning Strategy? - Consumer Eagle
07/20/16 06:50 PMPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Fundamental Star Rating Report - CML News
07/19/16 04:30 AMShare Performance Summary for: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Press Telegraph
07/19/16 04:30 AMTrading Performance and Target Watch for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Press Telegraph
07/19/16 04:30 AMShares of Portola Pharmaceuticals (PTLA) Drops by -7.25% - Trade Calls
07/19/16 04:30 AMWere Analysts Bullish Portola Pharmaceuticals Inc (NASDAQ:PTLA) This Week? - Consumer Eagle
07/18/16 11:27 AMPTLA March 2017 Options Begin Trading
07/16/16 09:13 AMShares Experiencing a Downtrend: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - TGP
07/15/16 04:58 PMCan Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Keep Up with Analyst Expectations? - Investor Newswire
07/13/16 06:22 PMPortola Pharmaceuticals Inc Just Recorded A Sigfniciant Decline - Consumer Eagle
07/13/16 08:54 AMPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Yearly Sales Target At $397.97 - Investor Newswire
07/12/16 06:14 PMShares Moving Up Over the Past Quarter: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Engelwood Daily
07/12/16 06:14 PMPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 10:21 AMOption Market: Portola Pharmaceuticals Inc Risk Hits An Elevated Level - CML News
07/12/16 10:21 AMWere Analysts Bearish Portola Pharmaceuticals Inc (NASDAQ:PTLA) This Week? - Engelwood Daily
07/12/16 10:21 AMStock on the Rise for the Quarter: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Engelwood Daily
07/12/16 10:21 AMStock Performance Rundown on: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Press Telegraph
07/12/16 10:21 AMPortola Pharmaceuticals Incorporated (NASDAQ:PTLA) Short Interest Decreased By 0.11% - Press Telegraph
07/07/16 06:02 PMPortola Pharmaceuticals Incorporated (NASDAQ:PTLA) Shorts Decreased by 0.11% After Short Covering - Engelwood Daily
07/06/16 10:36 AMSales of $365.42 expected for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Investor Newswire
07/06/16 10:36 AMBroker Outlook For The Week Ahead Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Fiscal Standard
07/04/16 10:37 AMWill Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Surprise This Quarter? - Investor Newswire
07/03/16 05:18 PMPortola Pharmaceuticals Incorporated (NASDAQ:PTLA) Shorts Decreased by 0.11% After Short Covering - Press Telegraph
07/03/16 05:18 PMHow Analysts Feel About Portola Pharmaceuticals Inc (NASDAQ:PTLA)? - Press Telegraph
07/03/16 05:18 PMShare Performance Recap for: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Press Telegraph
06/30/16 08:48 AMPortola Pharmaceuticals Inc. (PTLA) Jumps 5.96% on June 28 - Equities.com
06/28/16 05:54 PMPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Yearly Sales Target At $365.42 - Investor Newswire
06/27/16 10:05 AMHow Many Portola Pharmaceuticals Inc (NASDAQ:PTLA)'s Analysts Are Bullish? - Engelwood Daily
06/27/16 10:05 AMNext Weeks Broker Price Targets For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Fiscal Standard
06/26/16 05:02 PMStock Performance Focus on: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Press Telegraph
06/25/16 05:24 PMTime to Sell Portola Pharmaceuticals Inc After Today's Gap Down? - Press Telegraph
06/25/16 05:24 PMStock Tracing Lower on the Week Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Engelwood Daily
06/24/16 06:01 PMPortola Pharmaceuticals Incorporated (NASDAQ:PTLA) Shorted Shares Increased 2.99% After Market Selling - Press Telegraph
06/22/16 05:56 PMEarnings Review: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - iStreetWire
06/22/16 03:20 PMPORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/20/16 05:45 PMCommit To Purchase Portola Pharmaceuticals At $17.50, Earn 19.8% Annualized Using Options
06/20/16 02:06 PMETF’s with exposure to Portola Pharmaceuticals, Inc. : June 20, 2016 -
06/17/16 07:22 AMPortola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : June 17, 2016 -
06/10/16 06:16 PMTrend Of Rating Given To Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Investor Newswire
06/06/16 09:41 AMInvestors Focused Movers: Depomed, Inc. (NASDAQ:DEPO) , Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Street Updates
06/05/16 05:57 PMHow Analysts Rated Portola Pharmaceuticals Inc (NASDAQ:PTLA) Last Week? - HNN
06/02/16 09:00 AMStrong Sell Calls Count For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) At 0 - Investor Newswire - Strong Sell Calls Count For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) At 0Investor NewswireAnalyst score was 1.17. A quarter ago, the mean score was 1.17 and 0 were Strong Sell recommendations. Strong Buy calls were 2, the buy calls were 1 and sell calls on Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) were 0. The count of Hold ratings was 0.and more »
06/01/16 06:32 PMNews Sentiment For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Investor Newswire - News Sentiment For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)Investor NewswirePortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Average broker stands at 1.17 while it was 1.17 three months ago. The quarterly report of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) can be made public close to 2016-08-02. It is estimated by the recent ...and more »
06/01/16 08:54 AMPortola Pharma (PTLA) Commences Dosing in Cerdulatinib Phase 2a in r/r B-Cell and T-Cell Malignancies - StreetInsider.com - Portola Pharma (PTLA) Commences Dosing in Cerdulatinib Phase 2a in r/r B-Cell and T-Cell MalignanciesStreetInsider.comPortola Pharmaceuticals Inc. (Nasdaq: PTLA) announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have ...
06/01/16 08:54 AMPortola Pharmaceuticals Inc. (PTLA) is Trading Higher on Unusual Volume for May 30 - Equities.com - Portola Pharmaceuticals Inc. (PTLA) is Trading Higher on Unusual Volume for May 30Equities.comPortola Pharmaceuticals Inc. (PTLA) experienced unusually high volume on May. 30, as the stock gained 4.6% to a closing price of $27.50. The stock saw 1.55 million shares trade hands over the course of the day on 9,919 trades. Given that the stock's ...and more »
06/01/16 07:13 AMPortola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc. (NASDAQ:PTLA), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating ...
05/31/16 06:17 PMPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) went up 4.60%: The Coca-Cola Company (NYSE:KO), Flushing ... - KC Register - Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) went up 4.60%: The Coca-Cola Company (NYSE:KO), Flushing ...KC RegisterOn 27 May, Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced that the full results of its pivotal Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study were presented today for the first time in a late-breaking ...and more »

Social

About Portola Pharmaceuticals

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PTLA
  • CUSIP:
Key Metrics:
  • Previous Close: $24.20
  • 50 Day Moving Average: $24.40
  • 200 Day Moving Average: $27.48
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.37B
  • Beta: 0.99
  • Current Year EPS Consensus Estimate: $-5.23 EPS
  • Next Year EPS Consensus Estimate: $-4.61 EPS
Additional Links:
Portola Pharmaceuticals (NASDAQ:PTLA) Chart for Monday, July, 25, 2016